Laboratory for Drug Discovery, Harvard NeuroDiscovery Center

Therapeutic Approaches: Small Molecules

Therapeutic Areas of Expertise: Neurological Disorders

Center/Program Highlights: The Laboratory for Drug Discovery in Neurodegeneration (LDDN) was established to discover chemical agents from which we and others will develop a new generation of drugs to treat neurodegenerative diseases. To accomplish this goal, LDDN has recruited a permanent staff of industry-seasoned medicinal chemists, to work in close collaboration with principal investigators from the academic neuroscience community. In this way, LDDN helps transform discoveries in the basic biology of neurodegeneration and other therapeutic areas into opportunities for drug discovery. Since its creation in 2001, the LDDN has established a track record of progress, including more than 60 projects and multiple projects that have demonstrated efficacy in animal models of disease. In addition, the Laboratory for Drug Discovery has established several sponsored research agreements with biotechnology/pharmaceutical companies and five projects have been licensed and several others have been optioned.

Sources of Funding: Federal/State, Philanthropy, Disease Foundations

Industrial Partnerships: Yuma Therapeutics

Website

Institutional Affiliation(s): Brigham and Women?s Hospital, Harvard Medical School

Address:
Partners Research Building 4th Floor
65 Landsdowne Street
Cambridge
Massachusetts, 02139
United States

Center/Program Start Date: 2001

Number of Employees: 14